Expansion and reactivation of Ionis PrProfile (ION717) clinical trial for people with symptomatic prion disease

Author: Joaquín Castilla

The company Ionis Pharmaceuticals has just announced that the pause in recruitment for its PrProfile (ION717) study for people with symptomatic prion disease has been lifted. Important information to note:

  1. Resumption of recruitment: After a planned pause, recruitment for the PrProfile clinical trial has resumed globally.
  2. Expansion of test sites: All planned clinical trial sites for PrProfile are now active, including several additional sites that were not part of the initial enrolment phase. In total, 16 trial sites are available.
  3. Continuous progress: This resumption marks an important step in the development of potential treatments for prion diseases.

We remain hopeful for continued progress towards possible drug development and clinical trials that may lead to a treatment or cure for prion diseases.

Attached is a translation into Spanish that we have made on the Community Declaration. This document answers some important questions such as: How long will it take to complete PrProfile registration, where can people interested in participating in PrProfile go for more information, why does clinicaltrials.gov still say that recruitment is paused, did Ionis review any data during this recruitment pause, and is there a way to receive ION717 outside of the clinical trial, such as for people not eligible for this clinical trial, and is there a way to receive ION717 outside of the clinical trial, such as for people not eligible for this clinical trial?

You can visit https://clinicaltrials.gov/study/NCT06153966?cond=Prion%20Diseases&rank=2 for more information on the details of the clinical trial, including the full list of sites where the trial can currently be conducted.

More news

en_GBEnglish (UK)